The role of IR in cancer care: From chemo-embolisation to ablation.

For many people in Singapore facing a cancer diagnosis, one of the first questions is whether treatment must always mean major surgery, long hospital stays, or repeated cycles of systemic therapy. Interventional radiology, often shortened to IR, offers another important pathway in cancer care. Using image guidance such as ultrasound, CT, fluoroscopy, or MRI, interventional radiologists can target tumours with precision through needles, catheters, and other minimally invasive tools. In the right patient, these procedures can control disease, relieve symptoms, and support overall cancer management while reducing the physical burden of treatment.

IR is not a replacement for oncology, surgery, or radiation therapy. Instead, it is part of a multidisciplinary approach that may include medical oncologists, surgeons, radiation oncologists, hepatobiliary specialists, colorectal teams, and palliative care professionals. This matters in Singapore, where patients often seek care in tertiary hospitals, private specialist centres, and joint multidisciplinary tumour boards that align treatment with the cancer type, stage, liver function, performance status, and treatment goals. For some patients, IR may be used as a bridge to surgery. For others, it may provide local tumour control when surgery is not suitable, or symptom relief when cure is no longer possible but quality of life remains a priority.

What interventional radiology means in cancer care

Interventional radiology uses imaging to guide procedures inside the body with minimal disruption to surrounding tissues. In oncology, the field includes treatments delivered through blood vessels, through the skin, or into body cavities. The main advantage is precision. Instead of treating the entire organ or body, IR can focus treatment on a tumour or a specific area of disease.

This approach is especially relevant when tumours are difficult to remove surgically, when there are multiple lesions, or when the patient may not tolerate a large operation. It is also helpful when treatment needs to be repeated over time. In Singapore, where treatment decisions often balance efficacy, recovery time, work commitments, family responsibilities, and follow-up logistics, minimally invasive options can be particularly valuable. That said, suitability depends on many factors, including tumour type, location, spread of disease, kidney function, liver reserve, clotting status, and any previous treatments.

How IR fits into the cancer journey

IR can be used at different points in the cancer pathway. In some cases, it is done before surgery to shrink or control a tumour. In others, it is used after surgery or alongside systemic treatment to manage recurrence. It can also be used when a tumour is not removable or when the goal is symptom control rather than cure. Because these procedures are image-guided, the treatment can often be planned with a high level of anatomical precision. This helps clinicians preserve as much healthy tissue as possible while still attacking the cancer effectively.

Chemo-embolisation: Targeted treatment through the blood supply

Chemo-embolisation combines two concepts, chemotherapy and embolisation. Chemotherapy refers to anti-cancer drugs. Embolisation means intentionally blocking blood vessels. In transarterial chemoembolisation, commonly called TACE, the doctor delivers chemotherapy directly into the artery supplying the tumour and then blocks that blood flow. The aim is to trap the drug in the tumour region and starve the cancer of oxygen and nutrients. This dual action can produce a higher local effect than giving the drug through the bloodstream alone.

This technique is used most often for liver cancers, especially hepatocellular carcinoma, which is the most common primary liver cancer. It may also be used in selected patients with liver-dominant metastases, depending on the tumour biology and overall treatment plan. Liver tumours are particularly suitable for this approach because they often receive a major part of their blood supply from the hepatic artery, while normal liver tissue receives more blood from the portal vein. That difference allows the interventional radiologist to selectively treat the tumour-bearing arterial branches.

Who may be considered for chemo-embolisation

Chemo-embolisation is not suitable for everyone. The procedure is usually considered when the tumour cannot be removed surgically and when the patient has enough liver reserve to tolerate the reduction in blood flow. It is typically planned after careful review of scans, blood tests, liver function, and the presence or absence of portal vein obstruction or extensive spread outside the liver. In Singapore, this decision is usually made in a multidisciplinary setting, because the choice between surgery, ablation, liver-directed therapy, systemic treatment, or transplant-related pathways can be complex.

Patients should also understand that chemo-embolisation is usually not a one-time cure for all cases. It may be repeated if the tumour responds and the liver function remains adequate. Sometimes it is used to slow tumour growth, reduce symptoms, or support a broader treatment plan that includes targeted therapy or immunotherapy, depending on the cancer subtype and oncology guidance.

What the procedure involves

The procedure is usually done under local anaesthesia with sedation, although the exact approach depends on patient needs and institutional practice. A catheter is inserted, usually through the femoral artery in the groin or the radial artery in the wrist, and guided to the arteries feeding the tumour. Contrast imaging is used to map the vessels and ensure the treatment is delivered as selectively as possible. After the chemotherapy is infused, embolic material is used to block the blood flow.

After treatment, patients may experience post-embolisation syndrome, a cluster of expected symptoms that can include pain, fever, nausea, tiredness, and reduced appetite. These effects are usually temporary and are managed with medications and supportive care. Many patients can return home after a short observation period, although the exact length of stay depends on the complexity of the procedure and the patient’s condition. In Singapore, follow-up often includes blood tests and repeat imaging to assess tumour response, usually coordinated between the interventional radiology team and the treating oncologist or hepatologist.

Ablation: Destroying tumours with heat, cold, or energy

Ablation is another key IR technique in cancer care. It refers to destroying tumour tissue using extreme temperatures or energy delivered through a needle-like probe. The most common forms are radiofrequency ablation, microwave ablation, and cryoablation. Radiofrequency ablation uses alternating electrical current to generate heat. Microwave ablation uses electromagnetic energy to heat tissue more rapidly and can sometimes create a larger treatment zone. Cryoablation freezes the tumour, causing cell death through repeated freezing and thawing cycles.

Ablation is often used for small tumours, especially in the liver, kidney, lung, and bone. In selected patients, it can be a curative-intent option, particularly when surgery is not ideal or when a patient has a limited number of small lesions. It can also be used for local control when cancer has recurred in a specific spot. The best outcomes are usually seen when the lesion is well defined, accessible, and not too close to critical structures such as major bile ducts, bowel, or central blood vessels.

Why ablation matters for early or limited disease

For some patients, ablation may offer a balance between effectiveness and recovery time. A person with a small liver tumour, for example, may avoid a major liver resection and still achieve strong local control. In practical terms, this can mean shorter hospitalisation, less postoperative pain, and a faster return to normal routines such as work, caregiving, and daily transport across Singapore. However, the exact recovery experience varies widely, and the procedure still requires careful planning and follow-up.

Ablation also has a role in patients who are not fit for surgery because of age, lung disease, heart disease, cirrhosis, or other medical issues. It is important to remember that suitability depends on more than tumour size alone. Tumour number, location, proximity to vessels, and the overall stage of cancer all influence whether ablation is a good option. Sometimes, ablation is combined with embolisation, surgery, or systemic therapy to improve control of disease.

How ablation is performed

Most ablation procedures are guided by CT or ultrasound. After local anaesthesia and sometimes sedation or general anaesthesia, the doctor inserts a probe through the skin into the tumour. Energy is then delivered to kill the cancer cells. The treated tissue is gradually broken down and absorbed by the body over time. Because imaging is used throughout the procedure, the doctor can monitor probe position and treatment coverage in real time or near real time.

As with any procedure, there are risks. These may include bleeding, infection, injury to nearby structures, pain, and incomplete treatment if the tumour is too large or difficult to access. In some locations, ablation can also affect normal tissue near the tumour. For this reason, a specialist team will often review the imaging in detail before recommending the procedure. Patients should ask how the treatment fits with the overall care plan, whether repeat ablation might be needed, and what the follow-up scans will show.

Benefits, risks, and realistic expectations

IR oncology treatments are attractive because they are targeted, minimally invasive, and often associated with faster recovery than open surgery. They may reduce the need for prolonged hospitalisation and can be suitable for patients who need disease control without a major operation. In the right setting, they can also preserve organ function, which is especially important for the liver and kidney. For Singaporean patients managing work, caregiving, and transport demands, the possibility of shorter recovery time can be an important practical benefit.

At the same time, these procedures are not risk-free and they are not suitable for every tumour. Chemo-embolisation may cause temporary pain, fatigue, liver irritation, or a flare of symptoms after treatment. Ablation may be limited by tumour size, location, or proximity to vulnerable anatomy. Some cancers are simply better treated with surgery, systemic therapy, radiation, or a combination of approaches. The most trustworthy treatment decisions come from accurate staging, clear imaging, and honest discussions about goals of care.

Questions patients in Singapore can ask their care team

Before agreeing to an IR procedure, patients and families can ask:

• What is the goal of this treatment, cure, control, or symptom relief?
• Is this meant to replace surgery, delay it, or support another therapy?
• How many tumours are being treated, and where are they located?
• What are the common side effects, and how are they managed?
• Will I need to stay overnight, and what should I expect after discharge?
• How soon will I need follow-up scans or blood tests?
• If the treatment does not fully work, what is the next step?

These questions help patients make informed decisions and understand how IR fits into their broader cancer plan. They also support shared decision-making, which is central to good oncology care.

Why multidisciplinary cancer care matters in Singapore

Singapore’s healthcare system is well suited to multidisciplinary cancer care, with tumour boards and specialist collaboration common across public and private settings. This is especially important because IR procedures are highly dependent on detailed imaging review and coordination with oncology, surgery, anaesthesia, nursing, and medical follow-up. A patient with liver cancer, for example, may need discussion among a hepatobiliary surgeon, oncologist, hepatologist, and interventional radiologist before a recommendation is made.

Patients in Singapore also benefit from access to advanced imaging and established cancer centres, but access alone is not enough. The key is choosing the right procedure for the right patient at the right time. A small tumour near a blood vessel may be a poor candidate for ablation but better suited to another liver-directed therapy. A patient with multifocal liver disease may benefit more from chemo-embolisation than from surgery. A patient whose disease is controlled but who needs local treatment for a recurrence may be considered for ablation or repeat IR therapy. These decisions depend on evidence, expertise, and close follow-up.

If you or a family member is exploring IR for cancer care, it is reasonable to ask for a clear explanation of the treatment goal, expected benefits, and alternatives. IR can be a powerful part of cancer treatment, but its value is highest when it is integrated thoughtfully into a patient’s overall care plan. For Singapore patients, that means choosing a team that can explain the options in plain language, review the scans carefully, and align treatment with both medical needs and real-life priorities.

General medical information only: treatment decisions for cancer should always be made with a qualified doctor who can assess the full clinical picture, imaging, and laboratory results.